JAK1 and neoplasm: CRISPR–Cas9-mediated disruption of the Jak1 gene encoding for a central mediator of the IFN signalling pathway leads to IFN-unresponsive and completely MHC-deficient tumour cells (Extended Data Fig. 3a).